A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking Antibodies
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary) ; Troriluzole (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 05 Sep 2019 Planned End Date changed from 30 Jul 2019 to 30 Jul 2022.
- 05 Sep 2019 Planned primary completion date changed from 30 Jul 2019 to 30 Jul 2022.
- 31 Aug 2018 Biomarkers information updated